抗肿瘤坏死因子-α单克隆抗体治疗非感染性葡萄膜炎中国专家共识
Chinese expert consensus on treatment of non-infectious uveitis with anti-tumor necrosis factor-alpha monoclonal antibody
海峡两岸医药卫生交流协会风湿免疫分会眼免疫学组 张晓敏 1郑文洁2
作者信息
- 1. 天津医科大学眼科医院、眼视光学院、眼科研究所国家眼耳鼻喉疾病临床医学研究中心天津市分中心天津市视网膜功能与疾病重点实验室,天津300384
- 2. 中国医学科学院 北京协和医学院 北京协和医院风湿免疫科,北京100730
- 折叠
摘要
抗肿瘤坏死因子-α单克隆抗体是用于治疗自身免疫性疾病的主要生物制剂之一,其中阿达木单抗和英夫利昔单抗因其在治疗非感染性葡萄膜炎中具有良好的有效性和安全性,已在临床应用多年,但在中国尚缺乏相关专家共识或指南.为促进抗肿瘤坏死因子-α单克隆抗体在非感染性葡萄膜炎中的规范应用,海峡两岸医药卫生交流协会风湿免疫分会眼免疫学组联合国内葡萄膜炎领域资深专家在循证证据基础上形成此推荐意见,以期为临床开展工作提供指导和参考.
Abstract
Anti-tumor necrosis factor-a monoclonal antibody agents have been widely applied in the management of autoimmune diseases.Among them,Adalimumab and Infliximab have been used for years in clinical practice in treating non-infectious uveitis and achieved satisfactory effects and safety.However,no guideline or expert consensus for their usage is available in China currently.It hopefully promotes standardized clinical application of anti-tumor necrosis factor-α monoclonal antibody in treating non-infectious uveitis,together with other senior experts in uveitis,the Ocular Immunology Group of Immunology and Rheumatology Academy in Cross-Straits Medicine Exchange Association form this evidence-based recommendations for clinicians'reference.
关键词
非感染性葡萄膜炎/抗肿瘤坏死因子-α单克隆抗体/阿达木单抗/英夫利昔单抗/生物制剂/专家共识Key words
Non-infectious uveitis/Anti-tumor necrosis factor-α monoclonal antibody/Adalimumab/Inflixmab/Biologicals/Expert consensus引用本文复制引用
基金项目
中央高水平医院临床科研业务费资助(2022-PUMCH-C-008)
天津市医学重点学科(专科)建设项目(TJYXZDXK-037A)
出版年
2024
NETL
NSTL
维普
万方数据